AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00701194 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Early Intervention Foster Care (EIFC)
Description: The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
Study NCT00949091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally.
Study NCT01376037 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia(r) ML Scanner (MLS)
Description: The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.
Study NCT01376037 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: inactive placebo laser device
Description: non-therapeutic light application
Study NCT03176758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: A total knee arthroplasty surgery, which is not the intervention of interest
Study NCT02770469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linguistically and Culturally Tailored Information
Description: Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.
Study NCT02770469 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linguistically and Culturally Tailored Information
Description: Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.
Study NCT02770469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Stress Management
Description: Participants learned and practiced skills related to mindfulness, relaxation, stress reduction, rational thinking, improving coping, enhancing social support, anger management, and assertiveness training.
Study NCT02985203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Oral
Description: Oral vinorelbine plus cisplatin Followed by Metronomic oral Vinorelbine
Study NCT01435317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANM T30 CR®-System
Description: Stimulation for 4-6h/day for a time of 1 year
Study NCT03458663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena™ og ACTIV.A.C™ Therapy System.
Description: A vacuum assisted (negative pressure) system, Prevena ™ and ACTIV.A.C ™ therapy system have been developed to maintain drainage on closed incisions. The system also works by altering the cytokine profile locally so that it functions anti-inflammatory, by increasing local growth factors and promoting angiogenesis19. Negative pressure wound management (NPWM) such as Prevena ™ and ACTIV.AC ™ is a widely used tool with many different variations, but the evidence of effect remains sparse and more studies are required20. We believe that in a dry and closed incision such as the one after BCL surgery, in an area exposed to stretching during healing, it must be an advantage of maintaining drainage, reducing the anti-inflammatory response and increasing angiogenesis.
Study NCT04538196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resident education on documentation and coding
Description: Surgery residents will receive education on documentation and coding at the beginning of a particular surgical rotation vs the control group who will receive no education on documentation
Study NCT00586196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: 5 mg each day for 30 days
Study NCT00586196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated cornstarch One capsule daily for 30 days
Study NCT02025062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGA and geriatric follow-up
Description: The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
Study NCT04107259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.
Study NCT00266773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic pain therapeutic interactive voice response (TIVR) system
Description: Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
Study NCT04401644 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Novel laser inferometry test for CORONA virus
Description: detection of virus particles by light absorbtion patterns.
Study NCT01199900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Study NCT01199900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
Study NCT01199900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Study NCT01199900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
Study NCT01199900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
Study NCT01978873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel + Androgen deprivation therapy
Description: Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
Study NCT02063438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericostal suture technique
Study NCT02063438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracostal suture technique
Study NCT02704377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Undergo HRV and wear accelerometer to assess therapy complications
Description: Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
Study NCT02704377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo iDXA
Study NCT02704377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02704377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01199900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Study NCT01791010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Study NCT02704377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01908699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium 314d Modified Release Tablets
Description: Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
Study NCT01908699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
Study NCT01697501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interleukin 28B testing
Description: Blood sampling for IL28B genotyping
Study NCT00292903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief interpersonal psychotherapy
Description: IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.
Study NCT00292903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated referral for treatment as usual
Description: F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
Study NCT03939494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Encounter
Description: Contact will be made with participants via Face Time or Skype.
Study NCT03053232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Purse string suture device
Description: Using purse string suture device to close gastrointestinal perforation under endoscopy.
Study NCT03053232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoclips
Description: Using endoclips to close gastrointestinal perforation under endoscopy.
Study NCT03987685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oratopo
Description: Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
Study NCT01791010 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Training sham
Description: Conducting fake training with the aim of blind the control group
Study NCT01247038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metal on ceramic articulation
Description: Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup
Study NCT01247038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal-on-Metal
Description: Metal on Metal articulation
Study NCT03953118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Oral Product
Description: Oral azithromycin dosed at 1 gram per week for 3 weeks
Study NCT03822715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted dietary intervention
Description: Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
Study NCT03822715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care aromatase inhibitors
Description: standard of care aromatase inhibitors
Study NCT01534221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix drug eluting stent
Description: Biomatrix drug eluting stent
Study NCT02003898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed 530G Insulin Pump
Study NCT03953118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: Oral placebo tablet
Study NCT00095628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV
Study NCT00095628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00095628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00845780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: withdrawal or continuation of amiodarone therapy
Description: withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
Study NCT00845780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: withdrawal or continuation of amiodarone therapy
Description: withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
Study NCT00939757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral tablet
Study NCT03913442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.8 mg or 0.6 mg orally once daily
Description: Colchicine 0.8 mg orally once daily for 1.5 months, and then 0.6 mg once daily for the remainder of the time (1.5 months)
Study NCT03913442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
Study NCT02877537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plethysmography
Study NCT01716325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management weight loss plan endorsement.
Description: Self-management weight loss plan endorsement.
Study NCT01716325 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional
Description: Weight loss, comparator - no ICT support; conventional live workshops for weight loss
Study NCT01978873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy
Description: LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
Study NCT02508870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab as per the schedule described in individual cohort.
Study NCT02508870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Participants will receive azacitidine as per the schedule described in individual cohort.
Study NCT04483349 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT03123874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile pump set-up
Description: Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
Study NCT03123874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mother's Own pump set-up
Description: Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
Study NCT00453258 — intervention group
Intervention type: OTHER
Intervention: Eye Examination
Description: Subjects receiving eye examination
Study NCT02641873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: 240 mg twice daily (480 mg total daily dose)
Study NCT02641873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
Study NCT02641873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
Study NCT02641873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: 200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
Study NCT02641873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
Study NCT00697827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interspinous Spacer device
Description: Device: In-Space
Study NCT00697827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interspinous Process Distraction Device
Description: Device: X STOP
Study NCT01851876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Description: Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
Study NCT01889758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
Study NCT01575886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Teachable Moment Communication Process
Description: The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
Study NCT01575886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teachable Moment Communication Process
Description: The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
Study NCT02272985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [15O]H2O PET-CT scan
Description: All participants will undergo 3 \[15O\]H2O PET-CT scans during the hemodialysis study session
Study NCT02272985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NIRS (Invos)
Description: All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
Study NCT04585581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time-restricted eating
Description: Participants will be asked to limit the time-window for their daily energy intake to a maximum of 10 hours.
Study NCT04585581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity exercise
Description: Participants will be encouraged to exercise with high intensity 2-3 times per week
Study NCT04585581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard clinical care
Study NCT04585581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard clinical care
Study NCT04493138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT04493138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO
Study NCT03583515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-Specific Personalized Normative Feedback
Description: Participants will receive personalized normative feedback about drinking.
Study NCT03583515 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Social Media Personalized Normative Feedback
Description: Participants will receive personalized normative feedback about social media use.
Study NCT01280955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.